The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2024 | Advancements in immunotherapy for hepatocellular carcinoma
Ghassan Abou-Alfa, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses standard treatments for advanced hepatocellular carcinoma (HCC), such as atezolizumab plus bevacizumab and durvalumab plus tremelimumab, which show effective survival outcomes with limited toxicity. Camrelizumab plus rivoceranib show promise for patients with hepatitis B, similar to nivolumab and ipilimumab, but needs further study due to complex tumor microenvironments. Investigational therapies like livmoniplimab plus budigalimab are also being explored in the LIVIGNO-2 trial (NCT06109272), though accessibility remains a concern in regions like Africa where liver cancer cases are highest and advanced treatments are limited. This interview took place at 2024 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Annual Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
